Major Phase 3 Trial Finds Fecal Microbiota Transplant Does Not Relieve IBS Symptoms
The largest FMT trial in IBS to date shows donor stool transplants offer no benefit over placebo, challenging microbiome-centered treatment theories.
Summary
The REFIT2 trial, a rigorous phase 3 study conducted at five Norwegian hospitals, tested whether fecal microbiota transplantation (FMT) — delivering a healthy donor's gut microbiome via rectal enema — could meaningfully reduce symptoms in 448 adults with moderate-to-severe irritable bowel syndrome. After 90 days, about 40% of both the FMT group and the placebo group (who received their own stool back) showed meaningful symptom improvement. The difference between groups was a statistically insignificant 1.9 percentage points. Adverse events were similar in both arms. The findings indicate that simply reshaping the gut microbiome is unlikely to be sufficient to treat IBS, raising important questions about whether gut dysbiosis is a primary driver of the condition or a secondary feature of it.
Detailed Summary
Irritable bowel syndrome affects roughly 10% of the global population and remains poorly understood and difficult to treat. Because alterations in gut microbiota composition are frequently observed in IBS patients, fecal microbiota transplantation — the transfer of stool from a healthy donor to reset the recipient's gut ecosystem — has attracted considerable attention as a potential therapy. Earlier, smaller trials produced mixed but sometimes encouraging results, making a definitive phase 3 evaluation urgently needed.
REFIT2 enrolled 450 adults aged 18–65 with moderate-to-severe IBS, defined by Rome IV criteria and an IBS Severity Scoring System score of 175 or higher, at five Norwegian hospitals. Participants were randomized 2:1 to receive a single rectal enema of either healthy donor stool (intervention, n=299) or their own stool (placebo, n=151). The trial was fully double-blinded, with all investigators, clinicians, and patients masked to allocation. The primary endpoint was a reduction of 75 or more points on the IBS-SSS at 90 days.
The results were unambiguous: 40% of the FMT group and 38% of the placebo group met the primary endpoint, yielding an absolute difference of just 1.9 percentage points (95% CI −8.1 to 12.0; p=0.76). Safety profiles were similar between groups.
These null findings carry significant implications for the gut-microbiome field. Despite a biologically plausible rationale and real-world enthusiasm for FMT in IBS, the intervention conferred no detectable clinical benefit over autologous stool in this large, well-powered trial. The authors suggest that microbiota modulation alone may be insufficient for symptom relief, pointing toward a more complex, multifactorial pathophysiology involving gut–brain axis signaling, visceral hypersensitivity, or mucosal immune dysfunction.
For clinicians and the longevity-minded public, the study reinforces caution before embracing microbiome-targeted therapies for functional GI disorders. A notable limitation is that this summary is based on the abstract only; route of administration (single enema) and donor selection protocols may have influenced outcomes.
Key Findings
- FMT via rectal enema produced no significant IBS symptom benefit vs. autologous stool placebo at 90 days.
- Response rates were nearly identical: 40% (FMT) vs. 38% (placebo), a 1.9-point difference that was not statistically significant.
- Adverse event rates were comparable between donor FMT and placebo groups, confirming acceptable safety.
- Results suggest gut dysbiosis may be a secondary feature of IBS rather than a primary, targetable cause.
- A single-dose rectal enema delivery may be insufficient; future trials may need repeated dosing or colonoscopic delivery.
Methodology
REFIT2 was a parallel-group, randomized, double-blind, placebo-controlled phase 3 trial across five Norwegian hospitals enrolling 448 adults with moderate-to-severe IBS (Rome IV; IBS-SSS ≥175). Participants were assigned 2:1 to donor or autologous (self) stool delivered as a single rectal enema, with full masking of all parties. The primary endpoint was ≥75-point IBS-SSS reduction at 90 days.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; details on donor screening protocols, microbiome engraftment verification, and subgroup analyses are unavailable. A single rectal enema may represent a suboptimal delivery method or dosing schedule compared to colonoscopic or repeated-dose approaches used in other studies. The 90-day follow-up period may not capture longer-term microbiome shifts or delayed symptom effects.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: